Bruker Co. (NASDAQ:BRKR) – Stock analysts at Jefferies Financial Group upped their Q1 2020 earnings per share estimates for Bruker in a report released on Friday, June 21st. Jefferies Financial Group analyst B. Couillard now forecasts that the medical research company will post earnings of $0.41 per share for the quarter, up from their prior estimate of $0.40. Jefferies Financial Group currently has a “Buy” rating and a $56.00 target price on the stock. Jefferies Financial Group also issued estimates for Bruker’s Q3 2020 earnings at $0.45 EPS, Q4 2020 earnings at $0.56 EPS and FY2020 earnings at $1.84 EPS.
Several other research firms have also issued reports on BRKR. Barclays reiterated a “hold” rating and issued a $44.00 target price on shares of Bruker in a research note on Monday. Needham & Company LLC set a $57.00 target price on shares of Bruker and gave the stock a “strong-buy” rating in a research note on Monday. BTIG Research upped their target price on shares of Bruker to $57.00 and gave the stock a “buy” rating in a research note on Friday, June 21st. Bank of America reiterated a “neutral” rating and issued a $52.00 target price (up previously from $44.00) on shares of Bruker in a research note on Friday, June 21st. Finally, UBS Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $43.00 target price for the company in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Bruker presently has a consensus rating of “Buy” and a consensus price target of $48.20.
NASDAQ BRKR opened at $48.36 on Monday. Bruker has a 1 year low of $26.10 and a 1 year high of $49.88. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.27 and a current ratio of 2.12. The company has a market cap of $7.65 billion, a price-to-earnings ratio of 34.54, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. The business has a fifty day moving average price of $43.80.
Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, May 2nd. The medical research company reported $0.28 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.04. Bruker had a net margin of 9.53% and a return on equity of 26.28%. The firm had revenue of $461.40 million during the quarter, compared to analyst estimates of $450.46 million. During the same quarter in the prior year, the business posted $0.24 EPS. The business’s revenue was up 6.9% compared to the same quarter last year.
The business also recently declared a quarterly dividend, which was paid on Friday, June 21st. Investors of record on Monday, June 3rd were given a dividend of $0.04 per share. The ex-dividend date was Friday, May 31st. This represents a $0.16 annualized dividend and a yield of 0.33%. Bruker’s payout ratio is currently 11.43%.
In related news, CEO Frank H. Laukien sold 400,000 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $41.48, for a total transaction of $16,592,000.00. Following the completion of the transaction, the chief executive officer now owns 37,991,030 shares in the company, valued at $1,575,867,924.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Marc A. Kastner sold 1,374 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $41.79, for a total transaction of $57,419.46. Following the transaction, the director now owns 10,811 shares of the company’s stock, valued at approximately $451,791.69. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 801,374 shares of company stock valued at $33,241,419. 26.50% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in Bruker by 2.6% during the fourth quarter. BlackRock Inc. now owns 5,465,722 shares of the medical research company’s stock valued at $162,713,000 after purchasing an additional 139,004 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Bruker by 5.5% during the first quarter. Acadian Asset Management LLC now owns 4,212,522 shares of the medical research company’s stock valued at $161,930,000 after purchasing an additional 220,700 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Bruker by 10.7% during the first quarter. Janus Henderson Group PLC now owns 3,298,436 shares of the medical research company’s stock valued at $126,792,000 after purchasing an additional 319,125 shares during the last quarter. AJO LP lifted its holdings in Bruker by 9.0% during the first quarter. AJO LP now owns 2,229,209 shares of the medical research company’s stock valued at $85,691,000 after purchasing an additional 183,548 shares during the last quarter. Finally, Norges Bank purchased a new stake in Bruker during the fourth quarter valued at about $49,346,000. Institutional investors own 66.73% of the company’s stock.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.